Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: a clinical experience

Basit Öğe Kaydı
dc.authoridCETIN AKHAN, SILA/0000-0002-2540-2060
dc.authoridOZBEL, YUSUF/0000-0001-8335-1997
dc.authoridTatar, Bengu/0000-0003-3787-1734
dc.authoridYilmaz, Yusuf/0000-0003-4518-5283
dc.authoridERGUN, Nadide/0000-0002-2105-8004
dc.contributor.authorTatar, Bengu
dc.contributor.authorKose, Sukran
dc.contributor.authorErgun, Nadide Colak
dc.contributor.authorTurken, Melda
dc.contributor.authorOnlen, Yusuf
dc.contributor.authorYilmaz, Yusuf
dc.contributor.authorAkhan, Sila
dc.date.accessioned2024-09-18T20:26:41Z
dc.date.available2024-09-18T20:26:41Z
dc.date.issued2019
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractOBJECTIVE: The recent development of direct-acting antiviral agents (DAAs) has dramatically changed the treatment of chronic hepatitis C, and interferon-based regimes have become a poor treatment choice in clinical practice. Today DAAs offer shorter, well-tolerated, highly effective curative therapies. This study aimed to evaluate the effectiveness and safety of DAAs in patients with end-stage renal disease and HCV genotype 1 infection in real clinical practice. METHODS: Thirty-six patients who attended our clinic, were diagnosed with chronic hepatitis C (CHC), undergoing hemodialysis, and fulfilled the criteria of age >18 years, genotype 1 infection, with a detectable HCV RNA level were considered for the study. Patients with GT1a infection received OBV/PTV/r plus DSV plus RBV for 12 weeks; GT1b infected patients received this regimen without RBV for 12 weeks. RESULTS: The study was conducted on 33 patients. The mean age was 52.30 +/- 13.77 years, and 70 % of them were male. By the fourth week of treatment, HCV RNA levels decreased below 15 IU/ml in all patients. Sustained virologic response (SVR) 12 rate was 100%. Nine patients had side effects during treatment. Of the patients with side effects, 89.9% were in group 1a and 11.1% in group lb. CONCLUSION: In this study, treatment with OBV/PTV/r and DSV with or without RBV resulted in high rates of sustained virologic response in HCV GT1-infected patients with end-stage renal disease (ESRD). SVR was achieved in all patients with few side effects.en_US
dc.identifier.doi10.1590/1806-9282.65.12.1470
dc.identifier.endpage1475en_US
dc.identifier.issn1806-9282
dc.identifier.issue12en_US
dc.identifier.pmid31994628en_US
dc.identifier.scopus2-s2.0-85079644898en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1470en_US
dc.identifier.urihttps://doi.org/10.1590/1806-9282.65.12.1470
dc.identifier.urihttps://hdl.handle.net/20.500.12483/10480
dc.identifier.volume65en_US
dc.identifier.wosWOS:000510392000011en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAssoc Medica Brasileiraen_US
dc.relation.ispartofRevista Da Associacao Medica Brasileiraen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHepatitis Cen_US
dc.subjectEnd-Stage Renal Diseaseen_US
dc.subjectSustained Virologic Responseen_US
dc.titleResponse to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: a clinical experienceen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Tam Metin / Full Text
Boyut:
205.25 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu